Next Article in Journal
Surgical Considerations of Intractable Mesial Temporal Lobe Epilepsy
Next Article in Special Issue
The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids—A Systematic Review
Previous Article in Journal
New Insights into the Role of Neuron-Specific Enolase in Neuro-Inflammation, Neurodegeneration, and Neuroprotection
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Brain Sci. 2018, 8(2), 34; https://doi.org/10.3390/brainsci8020034

Octodrine: New Questions and Challenges in Sport Supplements

1
Research Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, Herts SP9 11FA, UK
2
Department of Pharmacy, Pharmacology and Clinical Science, University of Hertfordshire, Herts AL10 9AB, UK
3
Semey State Medical University, Republican Scientific and Practical Center of Mental Health, Pavlodar 140002, Kazakhstan
4
Faculty of Medicine, University of Baghdad, Baghdad 10071, Iraq
5
Parliamentary Office of Science and Technology, Houses of Parliament, London SW1A 0AA, UK
6
Navy General Hospital, Cardiovascular department, Alexandria 21513, Egypt
7
Department of Neuroscience, Imaging and Clinical Sciences, “G.d’Annunzio” University, 66100 Chieti, Italy
*
Author to whom correspondence should be addressed.
Received: 31 January 2018 / Revised: 16 February 2018 / Accepted: 17 February 2018 / Published: 20 February 2018
Full-Text   |   PDF [936 KB, uploaded 23 February 2018]   |  
  |   Review Reports

Abstract

Background: Octodrine is the trade name for Dimethylhexylamine (DMHA), a central nervous stimulant that increases the uptake of dopamine and noradrenaline. Originally developed as a nasal decongestant in the 1950’s, it has recently been re-introduced on the market as a pre-workout and ‘fat-burner’ product but its use remains unregulated. Our work provides the first observational cross-sectional analytic study on Octodrine as a new drug trend and its associated harms after a gap spanning seven decades. Methods: A comprehensive multilingual assessment of literature, websites, drug fora and other online resources was carried out with no time restriction in English, German, Russian and Arabic. Keywords included Octodrine’s synonyms and chemical isomers. Results: Only five relevant publications emerged from the literature search, with most of the available data on body building websites and fora. Since 2015, Octodrine has been advertised online as “the next big thing” and “the god of stimulants,” with captivating marketing strategies directed at athletes and a wider cohort of users. Reported side-effects include hypertension, dyspnoea and hyperthermia. Conclusions: The uncontrolled use of Octodrine, its physiological and psychoactive effects raise serious health implications with possible impact on athletes and doping practices. This new phenomenon needs to be thoroughly studied and monitored. View Full-Text
Keywords: octodrine; dimethylhexylamine; DMHA; ambredin; fitness; novel psychoactive substance; performance and image-enhancing drugs; anti-obesity agents; weight loss octodrine; dimethylhexylamine; DMHA; ambredin; fitness; novel psychoactive substance; performance and image-enhancing drugs; anti-obesity agents; weight loss
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Catalani, V.; Prilutskaya, M.; Al-Imam, A.; Marrinan, S.; Elgharably, Y.; Zloh, M.; Martinotti, G.; Chilcott, R.; Corazza, O. Octodrine: New Questions and Challenges in Sport Supplements. Brain Sci. 2018, 8, 34.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top